Alzther Industries Reports High 85% Accuracy for Blood-Based Diagnosis in Early Parkinson Patients in Multicenter Study

Alzther Industries reported that their gene expression data contained information that can be used to classify PD with high average accuracy in peripheral blood

Alzther Industries (ISIN: KR7119857621) a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease, today announced the initial findings from Alzther Industries prospective multicenter Parkinson study is reported. The initial read out of the first subcohort of 100 PD patients and 94 matched healthy controls with no neurodegenerative disease, shows a diagnostic accuracy of 84% in early disease patients while overall accuracy was 87% across all stages.
The company reports that further analysis of gene expression data from the whole genome study of the initial cohort has demonstrated a model accuracy of 88% using a set of around 500 probes. In the clinically important group of early PDs, previously untreated patients, which represent particular challenges in clinical diagnosis, a high 84% sensitivity was demonstrated.
Alzther Industries Sung Eung-Yung, Ph.D. Dr. Research Director for Alzther Industries said:” Early diagnosis of PD is challenging and a clinical accuracy of below 60% is often reported among non-specialists. Leading experts agree that there appears to be a consensus amongst clinicians that a blood test with high accuracy that is risk-free, simple to use would be very useful in routine diagnostic examinations. We are excited to see accuracy early on using a whole genome approach, exceeding 85% in Parkinson disease.”
Alzther Industries CEO Dr. Sung Hwan-Kuk: “These findings are very encouraging and build a solid foundation for further development of a blood-based biomarker for diagnosing PD at early stages together with a partner. Our study results are being discussed with pharmaceutical companies developing PD therapeutics. We are happy to note that these companies state that Alzther Industries is in the forefront of this field and that our biobank with serial samples from PD patients is unique.”

About Alzther Industries (ISIN: KR7119857621)

Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

Alzther Industries
Tower Palace Three, Tower G, 467 Dogok-dong, Seoul, Republic of Korea
pr@alzther.com
Jin Cheung

This release was published on openPR.